Stem cell-derived dopamine cell therapies for Parkinson’s disease: what have the first trials shown?
This scientific commentary refers to ‘Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson’s disease’ by Sawamoto et al. (https://doi.org/10.1038/s41586-025-08700-0) and ‘Phase I trial of hES cell-derived dopaminergic neurons for Parkinson’s disease’ by Tabar et al. (https://doi.org/10.1038/s41586-025-08845-y).
Authors
- Malin Parmar (ORCID: https://orcid.org/0000-0001-5002-4199)
- Roger A. Barker (ORCID: https://orcid.org/0000-0001-8843-7730)
Institutions
- Lund University (SE)
- Wellcome/MRC Cambridge Stem Cell Institute (GB)
Publication Details
- Journal
- Brain
- Published
- 2025-09-03
- DOI
- https://doi.org/10.1093/brain/awaf322
- Citations
- 1
- Primary Topic
- Neuroscience and Neural Engineering
- Type
- article
- Field-Weighted Citation Impact
- 0.91